Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

848.13 +12.45 (+1.49%)
Streaming Delayed Price Updated: 1:30 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
12 Analysts Have This To Say About argenx ↗
 
Via Benzinga
News headline image
Is argenx Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Assessing argenx: Insights From 11 Financial Analysts ↗
 
Via Benzinga
News headline image
Where argenx Stands With Analysts ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy ↗
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability. 
Via Chartmill
News headline image
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
3 Healthcare Pathbreakers With Long-Term Tailwinds ↗
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines. 
Via MarketBeat
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win ↗
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases. 
Via Benzinga
News headline image
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
News headline image
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
News headline image
Argenx Tops Buy Point On Bullish Study, 850 Price Target ↗
Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage. 
Via Investor's Business Daily
News headline image
Argenx Targets FDA Label Expansion After Vyvgart Trial Success ↗
Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025 
Via Benzinga
News headline image
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
ARGENX SE - ADR (NASDAQ:ARGX) Ticks Key Boxes for Growth Investors Using Navellier's 'Little Book' Strategy ↗
Discover ARGX, a top growth stock matching Navellier's criteria with explosive earnings growth, soaring sales, and a high 21% ROE. 
Via Chartmill
News headline image
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.